ReviewAdvances in ophthalmology practice and research
Transparent GelMA biomaterials: Advanced solutions for ocular tissue engineering and regenerative ophthalmology.
Review in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances in Extended Ocular Drug Delivery for the Ocular Surface.Molecules (Basel, Switzerland) · 2026Review
- A biomimetic and xeno-free platform for corneal engineering: synergy between PRGF technology and human dental pulp stem cells.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The complex and sensitive nature of ocular tissues demands innovative biomaterials for effective repair and regeneration. Gelatin methacryloyl (GelMA) hydrogel has emerged as a highly promising candidate due to its excellent biocompatibility, tunable mechanical properties, and adaptability to advanced fabrication techniques like 3D bioprinting. Main text: This review provides a comprehensive analysis of GelMA's applications across key areas of ocular surface therapy. It first covers its role in sutureless repair of corneal and conjunctival injuries, where photocurable adhesives offer rapid wound closure. A major focus is on artificial cornea development, detailing strategies for enhancing mechanical strength, incorporating bioactive components and utilizing 3D/4D printing to mimic native corneal architecture. Furthermore, GelMA serves as an effective platform to treat limbal stem cell deficiency (LSCD) and as a drug-eluting system for managing keratitis and dry eye, featuring stimuli-responsive release mechanisms. However, challenges remain, including immune response concerns, long-term biosafety of photoinitiators, and the lack of standardized manufacturing protocols. Conclusions: GelMA represents a versatile foundation for next-generation ophthalmic biomaterials. Future progress hinges on establishing long-term safety profiles, developing intelligent composites with precise spatiotemporal control, and overcoming the regulatory and scalability hurdles associated with personalized, cell-based therapies. This review aims to guide the translational pathway of GelMA from laboratory innovation to clinical reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.